New drug CRIS100 tested for spinal cord injury safety
NCT ID NCT05739734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether a single dose of CRIS100 is safe for people with a recent spinal cord injury in the upper back. Only 5 adults with severe injuries will receive the drug directly at the injury site within 72 hours. The study focuses on side effects and lab changes, not on curing the injury.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THORACIC SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.